Prosecution Insights
Last updated: November 15, 2026

Meristem Spa

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Meristem Spa currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific matter is assigned to 1 distinct examiner, KONOPKA, CATHERINE ANNE, who also serves as the busiest examiner for the portfolio. The prosecution activity is concentrated within 1 distinct art unit, reflecting a focused technical scope for the company patent portfolio.

Practitioners should note that with 1 pending office action and 1 distinct examiner, the current prosecution strategy is highly centralized. Because the busiest examiner handles the 1 busiest examiner pending matter, the outcome of this specific interaction will dictate the immediate progress of the company intellectual property. The reliance on 1 distinct art unit suggests that the pending application falls within a specialized regulatory or examination group within the Biotechnology & Pharmaceuticals sector.

This singular focus allows the legal team to concentrate their resources on the specific examination style of KONOPKA, CATHERINE ANNE. However, the lack of diversity in examiners or art units means that any procedural delays will affect the entire active portfolio. Navigating the active matter requires a precise response tailored to the technical standards of the assigned art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KONOPKA, CATHERINE ANNE 1 57.2% +66.3%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17817161 COMPOSITIONS AND METHODS FOR COMBINATORIAL ASSEMBLY AND SCREENING FOR FUNCTIONAL SITE-DIRECTED NUCLEOTIDE MODIFIERS KONOPKA, CATHERINE ANNE —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17817161 COMPOSITIONS AND METHODS FOR COMBINATORIAL ASSEMBLY AND SCREENING FOR FUNCTIONAL SITE-DIRECTED NUCLEOTIDE MODIFIERS KONOPKA, CATHERINE ANNE —

Top Art Units

Art UnitApps
1635 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17817161 COMPOSITIONS AND METHODS FOR COMBINATORIAL ASSEMBLY AND SCREENING FOR FUNCTIONAL SITE-DIRECTED NUCLEOTIDE MODIFIERS KONOPKA, CATHERINE ANNE 1635 §102§103§112 Final Rejection — Pending Aug 03, 2022

Managing Meristem Spa's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Meristem Spa have?

Meristem Spa has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Meristem Spa applications?

Catherine Anne Konopka has the most, with 1 of Meristem Spa's pending office actions.

What technology area are Meristem Spa's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month